Physician profile
Uday Kumar
NPI 1508886540
$1,363.07
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $369 · 2020: $181 · 2022: $36.85 · 2023: $424 · 2024: $352.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $603 · Education: $174.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $602.55 |
| Education | $174.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $504.51 | 2019-2020 | |
| Insmed, INC. | $204.99 | 2023-2024 | Arikayce |
| Merck Sharp & Dohme LLC | $201.62 | 2022-2024 | Zerbaxa, Dificid, Recarbrio |
| Astellas Pharma US INC | $141.18 | 2023-2024 | Cresemba |
| Abbott Laboratories | $74.73 | 2024 | Ensite |
| Shionogi INC | $56.29 | 2022-2023 | Fetroja |
| Boston Scientific Corporation | $53.04 | 2024 | Eluvia |
| Melinta Therapeutics, LLC | $32.68 | 2023 | Vabomere, Kimyrsa, Rezzayo |
| Inari Medical, INC. | $24.47 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Chiesi USA, INC. | $24.40 | 2023 | Cleviprex |
| Medline Industries Lp | $22.70 | 2020 | |
| Organogenesis INC. | $22.46 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Uday Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.